At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
Oxymetazolinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
In Brief
A Phase 3 clinical trial evaluating Oxymetazoline for Rosacea and Erythema. Completed, enrolled 50 participants across 1 site.
Detailed Summary
the study will measure the decrease in redness on the face of rosacea subjects
Study Details
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedNov 2017
Primary CompletionDec 2017
Study CompletionMar 2018
TodayJul 2026
First PostedNov 24, 2017
Enrollment StartOct 18, 2017
Primary CompletionDec 6, 2017
Study CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.6 years ago
Interventions
Oxymetazolinedrug
RLD